Kenvue: Modest Growth Puts $20.85 Fair Value at Risk
By stockpickr AI | March 3, 2026 | 10 min read
Investment Summary
Kenvue (KVUE) is a diversified consumer health company whose current valuation appears slightly overvalued based on a conservative DCF model assuming modest near-term growth.
Investment Recommendation
Hold
Fair Value: $20.85
Current Price: $22.22
Upside/Downside: -6.2%
The DCF analysis suggests an implied fair value slightly below the current market price of $22.22, indicating the stock is currently trading at a small premium. Valuation is driven primarily by stable, albeit moderate, projected free cash flow growth rather than explosive expansion.
Key Metrics
- Market Cap: $42.25B
- P/E Ratio: 36.76x
- Forward P/E: 18.10x
- Revenue Growth (YoY): 1.3%
- Net Margin: 13.0%
- ROE: 12.7%
- Debt/Equity: 0.68
- Dividend Yield: 2.25%
Strengths
- Defensive portfolio stability with strong brand equity across Oral Care, Self Care, and Skin Health.
- Solid recent operating cash flow generation, enabling consistent shareholder returns.
- Relatively low leverage compared to peers following the J&J spin-off structure.
- Positive trend in year-over-year revenue growth heading into 2024 (+1.3% TTM).
Risk Factors
- Intense competition in the beauty and personal care segments from digitally native brands and established giants.
- Ongoing brand revitalization efforts required for certain key categories, impacting marketing spend efficiency.
- FX headwinds and commodity cost inflation could compress gross margins if not fully passed on to consumers.
- Potential for slower future growth compared to high-growth technology sectors, given its mature industry.